4-(2-(4-chlorophenyl)-1-((4-chlorophenyl)amino)ethyl)benzene-1, 3-diol is a potential agent for gout therapy as a dual inhibitor of XOD and NLRP3

Add time:07/11/2019    Source:sciencedirect.com

BackgoundGout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Both anti-hyperuricemia and anti-inflammation could be gout therapeutic strategies, whereas ideal drugs for gout treatment are deficient.

We also recommend Trading Suppliers and Manufacturers of 3-[1-(4-chlorophenyl)-1H-tetraazol-5-yl]-7-methyl-4-phenylquinoline (cas 299463-14-2). Pls Click Website Link as below: cas 299463-14-2 suppliers

Prev:A study of effects of peptide fragments of bovine and human lactoferrins on activities of three key HIV-1 enzymes
Next:Temperature dependence of the Raman spectrum of 1-(4-chlorophenyl)-3-(2-thienyl)prop-2-en-1-one)